Status:
COMPLETED
12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who c...
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes
- Hb1AC \>7%-11% inclusive
- Male and females 18-70; females must be post-menopausal
- On a stable dose of metformin hydrochloride
Exclusion
- Medical history of stroke, unstable angina, heart attack within one year of enrollment, and alcohol dependency or recent drug abuse.
- Women of childbearing potential, pregnant or nursing
- Evidence of diabetic complications with significant end-organ damage
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
303 Patients enrolled
Trial Details
Trial ID
NCT00473525
Start Date
July 1 2007
End Date
June 1 2008
Last Update
June 24 2010
Active Locations (79)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
2
Pfizer Investigational Site
Gilbert, Arizona, United States, 85296
3
Pfizer Investigational Site
Phoenix, Arizona, United States, 85013
4
Pfizer Investigational Site
Phoenix, Arizona, United States, 85016